What is your approach to treating early stage EBV-positive diffuse large B-cell lymphoma of the elderly after a CR to systemic therapy?

This is a recently described entity with poor prognosis, so even with a CR after RCHOPx6 cycles, is your bias to push for ISRT due to EBV being poor prognosticator? If so, what dose would you recommend?

Answer from: Radiation Oncologist at Academic Institution

EBV+ diffuse large B-cell lymphoma of the elderly, which typically affects apparently immunocompetant individuals > 50 y/o, was a provisional diagnosis in the 2008 edition of the WHO classification system. EBV+ DLBCL has been recognized in younger patients which led to a revision in the 2016 clas...

Comments

Medical Oncologist at NYU Langone Medical Center
In a young patient with stage IV EBV + DLBCL NOS (...

Please select the option that best describes you:

What is your approach to treating early stage EBV-positive diffuse large B-cell lymphoma of the elderly after a CR to systemic therapy?

Related Questions